Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MERREM I.V. 2g as a 3 hour infusion every 8 hours
MERREM I.V. as a 3 hour infusion every 8 hours · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| MERREM I.V. 2g as a 3 hour infusion every 8 hours | DRUG | - |
| vancomycin I.V. 1 g every 12 hours | DRUG | - |
| tobramycin I.V. 5 mg/kg every 24 hours | DRUG | - |
| MERREM I.V. 1g as a 30 minute infusion every 8 hours | DRUG | - |
| MERREM I.V. 500 mg as a 3 hour infusion every 8 hours | DRUG | - |
Inclusion Criteria: * Onset or exacerbation of pneumonia at least 72 hours after admission to an acute care facility or onset of pneumonia in a nursing home or rehabilitation facility with subsequent transfer to an acute care facility * Diagnosis of hospital-acquired pneumonia requiring mechanical ...
Top 4 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tozorakimab |
| GSK plc Sponsored ADR | GSK | 3 | PHASE1 | Pn-MAPS30plus |
| Agenus Inc. | AGEN | 1 | PHASE2 | agenT-797 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | V175, V175A |
MERREM I.V. is used to treat pneumonia, including ventilator-associated pneumonia and hospital-acquired pneumonia in patients who require mechanical ventilatory support. It is given as a 3 hour infusion every 8 hours. The studied indication covers adults 18 years and older with these serious hospital-acquired lung infections.
MERREM I.V. is developed and marketed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the company behind the 3 hour infusion every 8 hours dosing regimen studied in hospitalized pneumonia patients.
MERREM I.V. has been studied in a Phase 3 clinical trial for pneumonia. That trial, NCT00050401, is completed and enrolled 500 participants. The study was conducted in the United States and included adults 18 years and older, both male and female, who were not healthy volunteers.
MERREM I.V. was evaluated in the Phase 3 trial NCT00050401, titled Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support. The trial is completed and enrolled 500 participants across the United States. It was an uncontrolled study without randomization or double blinding, and it enrolled adults aged 18 years and older.
Yes. MERREM I.V. 2g as a 3 hour infusion every 8 hours refers to the same product as MERREM I.V. The longer name simply specifies the 2 gram dose given as a 3 hour infusion every 8 hours, which is the dosing regimen studied in the Phase 3 pneumonia trial NCT00050401.